{
  "docId": "019de073-7953-75ff-b7a7-421adee0c76c",
  "docSlug": "f2ba5faea717d1fc1a89b119873b0327",
  "documentTitle": "Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides",
  "authorId": "anebulo-pharmaceuticals",
  "authorName": "Anebulo Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 53,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7953-75ff-b7a7-421adee0c76c/21",
  "deckHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c",
  "deckJsonHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c.json",
  "deckAnchorHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.85,
        "x": 0.08,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Three circular icons representing Pharmacology, Safety, and Efficacy",
      "attrs": null,
      "subkind": "other",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80edd275-cc14-4fbd-8c4c-b34cee7b86b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.66,
        "y": 0.54
      },
      "kind": "list",
      "text": "Positive proof of concept data in Phase 2 Part A THC challenge study; Substantial reduction in feeling high, reduction in THC-induced effects on body sway/heart rate; Improved alertness; Data supported testing lower doses of ANEB-001 and a higher dose of THC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a30b8ee-c257-4b91-baa4-bc78109bee5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.36,
        "y": 0.54
      },
      "kind": "list",
      "text": "More than 140 subjects have been dosed with oral ANEB-001 to date: 80+ in Phase 1 and 50+ in Phase 2; Well tolerated after dosing for up to 4 weeks in Phase 1 - no serious AEs; All Phase 2 Part A adverse events mild and transient except one case of moderate nausea/vomiting",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "827fa42a-2e6c-4eed-88cb-648d72643623",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.06,
        "y": 0.54
      },
      "kind": "list",
      "text": "Potent CB1 receptor antagonist; Oral bioavailability and half-life expected to support single dose product; Extensive Phase 1 PK data from previous development studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0f151ee-d427-4c02-b591-020c6a1a56b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "ANEB-001 Development for ACI: Background",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44297496-0857-4621-a9b9-ef55ed7bb407",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 48,
      "from": 13,
      "beatId": "684e64de-8d19-434b-83aa-4bfe1e4eb804",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 13-48 present ANEB-001 as a solution, detailing its pharmacology, clinical trial results, and development plan.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 20,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "1f2417df-59a7-4dba-a852-ef433df43395",
      "evidence": "The loop is opened by providing an update on ANEB-001's clinical development (slide 20) and closed by presenting positive results from the clinical trial (slides 24).",
      "position": 1,
      "objective": "How does ANEB-001 perform in clinical trials?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}